Charges lead to large first-quarter loss for Chiron
This article was originally published in Clinica
Due to a $349 million charge mainly related to its partnership with Ciba, Chiron recorded a net loss of $386 million compared with net income of $4.8 million in the first quarter a year earlier. Sales jumped to $218 million from $91 million because of increased product sales through newly-acquired diagnostics subsidiary Ciba Corning and Chiron's full ownership of vaccine manufacturer Biocine.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.